Related Experiment Videos
Haemodynamic effects of nifedipine and propranolol in patients with hypertrophic obstructive cardiomyopathy
Insights
Combined nifedipine and propranolol therapy significantly improved hemodynamics in patients with hypertrophic obstructive cardiomyopathy. This combination offers a promising alternative treatment for managing this condition.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertrophic obstructive cardiomyopathy (HOCM) is a complex condition characterized by left ventricular outflow tract obstruction.
- Current treatments aim to improve hemodynamic parameters and patient symptoms.
Purpose of the Study:
- To evaluate the hemodynamic effects of nifedipine, propranolol, and their combined administration in patients with HOCM.
- To compare the efficacy of combined therapy versus monotherapy.
Main Methods:
- Hemodynamic parameters were assessed in 12 HOCM patients.
- Measurements included left ventricular pressures, blood pressure, and cardiac output during spontaneous rhythm and atrial pacing.
- Drugs studied: nifedipine, propranolol, and their combination.
Main Results:
- Combined nifedipine and propranolol reduced left ventricular peak systolic pressure, systolic blood pressure, and total peripheral resistance.
- A significant reduction in the resting left ventricular outflow gradient was observed.
- Heart rate decreased, while cardiac index remained unchanged.
- Correlation found between baseline left ventricular end-diastolic pressure and its reduction.
Conclusions:
- Combined administration of nifedipine and propranolol demonstrates superior hemodynamic benefits compared to nifedipine alone in HOCM.
- This combination therapy represents a potentially valuable alternative treatment option for patients with hypertrophic obstructive cardiomyopathy.
Abstract:
The haemodynamic effects of nifedipine, propranolol, and the combined administration of the two drugs were studied in 12 patients with hypertrophic obstructive cardiomyopathy. The combined administration of nifedipine and propranolol appeared to be superior to that of nifedipine alone. The spontaneous heart rate was reduced in most cases after nifedipine plus propranolol, and at atrial pacing the following results were obtained: left ventricular peak systolic pressure was reduced from 200 +/- 39 to 157 +/- 30 mmHg; a positive correlation was found between the pre-drug left ventricular end-diastolic pressure and the magnitude of reduction in left ventricular end-diastolic pressure; systolic blood pressure was reduced from 125 +/- 31 to 111 +/- 27 mmHg, and total peripheral resistance was reduced from 1403 +/- 307 to 1160 +/- 209 dyne s-1 cm-5. The combined administration reduced the resting left ventricular outflow gradient from 76 +/- 19 to 45 +/- 26 mmHg, while cardiac index was left unchanged. The effects on mean pulmonary arteriolar resistance and mean pulmonary arteriolar resistance and mean pulmonary capillary venous pressure were in most cases slight and insignificant. The results indicate an improved haemodynamic condition in patients with hypertrophic obstructive cardiomyopathy after the combined administration of nifedipine and propranolol: a treatment that might provide a new and useful alternative to already existing medication.